Premium
Terbutaline Depot Tablets in Childhood Asthma
Author(s) -
Foged N.,
Høst A.,
Ljungholm K.
Publication year - 1985
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1985.tb00256.x
Subject(s) - terbutaline , medicine , depot , asthma , lung function , anesthesia , bronchodilator , pediatrics , lung , archaeology , history
Thirty children 8–13 years old, with perennial asthma and with a reversibility of ≥ 20 % in lung function (FEV 1 ) were given a sustained‐release preparation of terbutaline sulphate 5 mg twice a day and ordinary tablets 2.5 mg three times a day; each treatment lasted 1 week. The design of the study was double‐blind, cross‐over, with a randomized allocation of the drugs. Both drugs improved the lung function significantly. The children had significantly less coughing during the night when they took depot tablets than when they took ordinary tablets. The side effects were few with both treatments. Most of the patients preferred the depot tablets.